Key statistics
As of last trade, Fibrobiologics Inc (SG0:FRA) traded at 0.334, 95.32% above the 52 week low of 0.171 set on Jan 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.334 |
|---|---|
| High | 0.334 |
| Low | 0.334 |
| Bid | 0.334 |
| Offer | 0.374 |
| Previous close | 0.25 |
| Average volume | 6.67k |
|---|---|
| Shares outstanding | 67.59m |
| Free float | 55.70m |
| P/E (TTM) | -- |
| Market cap | 28.36m USD |
| EPS (TTM) | -0.444 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 07:00 GMT.
More ▼
Announcements
- FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
- FibroBiologics to Present at the BIO Investment & Growth Summit
- FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
- FibroBiologics Granted Extension by Nasdaq to Regain Compliance
- FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
- FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
- FibroBiologics to Present at the DealFlow Discovery Conference
- FibroBiologics CEO Issues Letter to Shareholders
- FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
- FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
More ▼
